Statement: cohorts 1 and 2 of the primary trial recorded a different number of patients that suffered from Congestive Heart Failure.
Primary_evidence: Outcome Measurement:    Congestive Heart Failure Rate   Clinical congestive heart failure includes patients with symptomatic decline in LVEF to at or below the lower limit of normal (LLN), or symptomatic diastolic dysfunction. 223 treated patients were included in the analysis.   Time frame: assessed on day 1 of cycles 5, 9, 17 and 25, and at end of treatment, then every 3 months for <2 years and every 6 months for 2-3 years from study entry Results 1:    Arm/Group Title: Arm A (ddBAC > BT > B)   Arm/Group Description: Dose dense bevacizumab, cyclophosphamide and doxorubicin, followed by paclitaxel and bevacizumab, followed by bevacizumab   Overall Number of Participants Analyzed: 103   Measure Type: Number   Unit of Measure: percentage of participants  2.9        (0.6 to 8.3) Results 2:    Arm/Group Title: Arm B (ddAC > BT > B)   Arm/Group Description: Dose dense doxorubicin and cyclophosphamide, followed by paclitaxel and bevacizumab, followed by bevacizumab   Overall Number of Participants Analyzed: 120   Measure Type: Number   Unit of Measure: percentage of participants  2.5        (0.5 to 7.1)